Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
3.6
Journals
Current Oncology
Special Issues
Treatment Strategies for Advanced Urothelial Carcinoma
share announcement

Treatment Strategies for Advanced Urothelial Carcinoma

A Special Issue of Current Oncology (ISSN 1718-7729) belonging to the section "Genitourinary Oncology".

Deadline for manuscript submissions: 30 September 2026 | Viewed by 561

Editor

Dr. Manojkumar Bupathi

E-Mail Website
Guest Editor
Rocky Mountain Cancer Centers, Greenwood Village, CO, USA
Interests: breast cancer; clinical research; sarcomas; urologic cancer

Special Issue Information

Dear Colleagues,

Advanced and metastatic urothelial carcinoma (UC) remains a significant clinical challenge, with historically poor survival outcomes despite recent therapeutic advancements. The management of these patients has evolved beyond traditional platinum-based chemotherapy to include immune checkpoint inhibitors, targeted therapies, and combination regimens, which have shown promising efficacy in selected populations. Personalized treatment strategies, guided by molecular profiling and predictive biomarkers, are increasingly shaping clinical decision-making. Moreover, understanding mechanisms of resistance and optimizing sequencing of therapies are critical for improving long-term outcomes. In addition to systemic treatment, multidisciplinary approaches integrating surgery and radiotherapy may offer benefits in selected cases.

This Special Issue will gather high-quality contributions that address the latest developments in therapeutic strategies for advanced or metastatic UC. We welcome original research, clinical trials, retrospective studies, and comprehensive reviews on topics including novel systemic therapies, immunotherapy combinations, biomarker-driven treatment approaches, and real-world management strategies. Studies assessing treatment outcomes, toxicity profiles, and cost-effectiveness are also highly encouraged.

Dr. Manojkumar Bupathi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • advanced urothelial carcinoma
  • metastatic bladder cancer
  • FGFR-targeted therapy
  • immune checkpoint inhibitors
  • PD-L1 expression
  • therapeutic sequencing
  • combination therapy
  • treatment resistance
  • clinical outcomes
  • personalized oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 787 KB  
Article
Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma
by İlkay Çıtakkul, Hayati Arvas, Mert Karaoğlan, Bahadır Köylü, Nazan Demir, Gözde Balkaya Aykut, Elif Şahin, Mesut Yılmaz, Zuhat Urakçı, Duygu Bayır Garbioğlu, Fatih Selçukbiricik, Ece Baydar, Beşire Nurdan Tazebay, Melike Yazıcı, Yasemin Bakkal Temi, Devrim Çabuk, Kazım Uygun and Umut Kefeli
Curr. Oncol. 2026, 33(9), 529; https://doi.org/10.3390/curroncol33090529 - 2 Sep 2026
Viewed by 70
Abstract
Second-line chemotherapy is widely used in metastatic urothelial carcinoma after progression on first-line platinum-based therapy, but its independent contribution to survival, as opposed to selection of healthier patients, remains unclear. In this multicenter retrospective cohort of 142 patients treated with first-line platinum-based chemotherapy [...] Read more.
Second-line chemotherapy is widely used in metastatic urothelial carcinoma after progression on first-line platinum-based therapy, but its independent contribution to survival, as opposed to selection of healthier patients, remains unclear. In this multicenter retrospective cohort of 142 patients treated with first-line platinum-based chemotherapy across seven Turkish centers, overall survival (OS) from first-line progression was compared between patients who received second-line chemotherapy (n = 80) and those who did not (n = 62), using multivariable Cox regression, inverse probability of treatment weighting (IPTW), propensity-score matching, landmark analysis, and a time-dependent Cox model. Median OS was 7.4 versus 4.7 months (log-rank p = 0.064). Second-line chemotherapy was independently associated with improved OS on multivariable analysis (adjusted hazard ratio [aHR] 0.620; 95% confidence interval [CI] 0.423–0.907; p = 0.014); Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 (aHR 3.881; p = 0.001) and lower albumin (aHR 0.671; p = 0.018) were also independent predictors. The association remained significant after IPTW (HR 0.648; p = 0.025) and after a time-dependent Cox model (HR 0.632; p = 0.019), and was unchanged in ECOG-restricted and Bellmunt-adjusted analyses (p = 0.008, p = 0.029); it narrowly missed significance after propensity-score matching (HR 0.645; p = 0.051) and did not reach significance in the 3-month landmark analysis (HR 0.743; p = 0.180). Power was limited (~49%). In a time-dependent Cox model—the analysis least susceptible to immortal-time bias, as it retains the full cohort and classifies pre-treatment person-time as unexposed—second-line chemotherapy remained independently associated with improved OS (HR 0.632; p = 0.019), closely consistent with the primary multivariable estimate. The conventional Cox, IPTW, and propensity-score-matched analyses, which treat second-line receipt as a baseline exposure, were directionally concordant but share a common time-related bias and are therefore not independent confirmations. ECOG performance status was a consistent predictor throughout. Full article
(This article belongs to the Special Issue Treatment Strategies for Advanced Urothelial Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop